-
Company Insights
Innovation and Patenting activity of Torii Pharmaceutical Co Ltd Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Torii Pharmaceutical Co Ltd Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will...
-
Product Insights
House Dust Mite Allergy – Drugs In Development, 2023
Global Markets Direct’s, ‘House Dust Mite Allergy - Drugs In Development, 2023’, provides an overview of the House Dust Mite Allergy pipeline landscape. The report provides comprehensive information on the therapeutics under development for House Dust Mite Allergy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Hyperphosphatemia – Drugs In Development, 2023
Global Markets Direct’s, ‘Hyperphosphatemia - Drugs In Development, 2023’, provides an overview of the Hyperphosphatemia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hyperphosphatemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Allergic Asthma – Drugs In Development, 2023
Global Markets Direct’s, ‘Allergic Asthma - Drugs In Development, 2023’, provides an overview of the Allergic Asthma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Allergic Asthma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Human Papillomavirus Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Human Papillomavirus Infections - Drugs In Development, 2023’, provides an overview of the Human Papillomavirus Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Human Papillomavirus Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Company Profile
Torii Pharmaceutical Co Ltd – Company Profile
Torii Pharmaceutical Co Ltd (Torii Pharma), a subsidiary of Japan Tobacco Inc, manufactures and markets pharmaceuticals for the treatment of renal diseases, skin diseases and allergies. The company’s marketed portfolio spans topical corticosteroids, therapeutic agents for hyperphosphatemia, oral therapeutic agents for pruritus and therapeutic agents for hyperkalemia. It also offers Japanese cedar pollen sublingual drops, Japanese cedar pollen sublingual tablets, and house dust mite sublingual tablets for the treatment of various allergies. Torii Pharma markets its products through its network...
Add to Basket -
Product Insights
House Dust Mite Allergy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
House dust mite allergy is an allergic reaction to tiny bugs that commonly live in house dust. Symptoms include frequent sneezing, a runny, stuffy, itchy nose and irritated eyes. Asthma and eczema can also be triggered by a dust mite allergy. Symptoms often worsen when the individual comes in close proximity to disturbed dust. The House Dust Mite Allergy - Drugs In Development research report provides a comprehensive overview on the therapeutics under development for House Dust Mite Allergy, complete...
-
Sector Analysis
Supportive Care in Cancer – Comprehensive Overview, Pipeline Products, Research and Development Strategies and Unmet Needs
Supportive care in cancer is an evolving discipline of medicine that is critical for holistic management of patients with cancer. With significant advancements being made in treatment of cancer particularly through development of immuno-oncology (IO) and targeted therapies, it is of equal significance to focus on supportive care in cancer so as to ensure that patients are able to complete the treatment cycle for the primary cancer as well as to enhance their quality of life. The report leverages on...
-
Sector Analysis
Human Immunodeficiency Virus (HIV): Competitive Landscape to 2026
Human immunodeficiency virus (HIV) is a retrovirus that impairs and destroys the host’s immune system, specifically targeting CD4 cells. Once an infected person has a CD4 cell count of less than 200 cells/μL, HIV has developed into acquired immunodeficiency syndrome (AIDS). This report provides an assessment of the pipeline, clinical, and commercial landscape of HIV. Overall, GlobalData expects new drug approvals to drive HIV market growth over the next decade (2016–2026).
-
Sector Analysis
Competitor Landscape: Renal Anemia
Sociable Pharma’s ‘Treatment Landscape’ contains evaluations of ongoing development activities within the Renal Anemia market, analysis of current & potential future product positioning, and forecast approval dates (by quarter) for candidates in Phase II development, or higher